Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Negative agreement of T-Track® CMV, QuantiFERON®-CMV and iTAg™ MHC Tetramers with CMV serology in hemodialysis patients

From: Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients

Test CMV negative serologya CMI- CMI+ negative agreement 95% CI
T-Track® CMV 57 45 12 0.789 0.661–0.886
 CMV aIE-1 57 45 12 0.789 0.661–0.886
 CMV app65 57 56 1 0.982 0.906–1.000
QuantiFERON®-CMVb 55 48 7 0.873 0.755–0.947
iTAg™ MHC Tetramers 45 42 3 0.933 0.817–0.986
  1. aCMV-serology served as primary reference measurement procedure; bcalculation of the negative agreement and associated 95% CI do not take into account the 2 indeterminate QuantiFERON®-CMV results out of the 57 CMV-seronegative patients; CMI- negative test result, CMI+ positive test result, CI confidence interval